Yes, the high rollover does suggest no safety issues and hopefully ticks that box amongst the FDA criteria, but it doesn’t improve my “confidence” of efficacy and a successful P3 result. Lilac dropout rates would be great to know, so my “confidence” is supported by our ability to match P2 results (with better knowledge and larger cohort), Lilac 2 centres still opening and as Little T states; the impressive spend Acadia have put on the table.
ACADIA earnings, page-69
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |